No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
www.towayakuhin.co.jpNo one on the platform currently holds 4553.T.
No tracked institution reports a position in 4553.T as of their last filing.
No one on the platform has traded 4553.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 2.6% | 3.5% | 5.1% | — | — | — |
| Rev. Growth % | 5.4% | 12.1% | ||||
| Profit Margin % | 1.9% | 5.4% | 7.5% | |||
| Free Cash Flow Margin % | 3.0% | -3.6% | -0.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $306.6B | +10.3% | $469.88 | $438.80–$576.91 | — | 6 |
| 2028 | $331.7B | +8.2% | $467.83 | $439.20–$513.94 | — | 6 |
| 2029 | $343.7B | +3.6% | $497.10 | $464.10–$556.60 | — | 5 |
| 2030 | $358.5B | +4.3% | $500.80 | $489.48–$511.97 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-14 | $107.89 | $-240.35 | -322.8% |
| 2026-02-13 | $73.56 | $180.15 | +144.9% |
| 2025-11-10 | $62.02 | $115.80 | +86.7% |
| 2025-08-07 | $63.46 | $51.06 | -19.5% |
| 2025-05-15 | $113.89 | $88.61 | -22.2% |
| 2025-02-13 | $57.66 | $163.93 | +184.3% |
| 2024-11-12 | $49.62 | $21.53 | -56.6% |
| +0.78% |
| $114.9B |
| — |
| 4547.TKissei Pharmaceutical Co., Ltd. | $4015.00 | -0.12% | $166.4B | — |
| 4559.TZeria Pharmaceutical Co., Ltd. | $2014.00 | -0.10% | $88.8B | — |
Source: Financial Modeling Prep · peers by sector/industry